Novartis’ Panobinostat Review Pits Progression-Free Survival Against Toxicities
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will also consider whether appropriate dose was selected for Phase III trial of the oral deacetylase inhibitor in patients with relapsed multiple myeloma.
You may also be interested in...
Expanded Access Opens Window For Dose Optimization Studies In Cancer
The period after completion of pivotal trials but ahead of FDA approval provides an opportunity for oncology drug sponsors to conduct badly needed dose comparison trials, a multi-stakeholder panel says at the annual Conference on Clinical Cancer Research.
US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.
Monkeypox Vaccine: US FDA Eyes Dose-Sparing Strategy For Jynneos
Switching method of administration from subcutaneous to intradermal would increase by five-fold the number of doses of Bavarian Nordic’s vaccine available to combat the outbreak; an EUA declaration would be needed to make this change, FDA commissioner Robert Califf said.